Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Retained Earnings (2019 - 2025)

Silo Pharma's Retained Earnings history spans 7 years, with the latest figure at -$18.6 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 37.51% year-over-year to -$18.6 million; the TTM value through Sep 2025 reached -$18.6 million, down 37.51%, while the annual FY2024 figure was $2419.0, 100.02% up from the prior year.
  • Retained Earnings for Q3 2025 was -$18.6 million at Silo Pharma, down from -$17.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $26104.0 in Q1 2024 and bottomed at -$18.6 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$7.2 million (2022), against an average of -$7.0 million.
  • The largest YoY upside for Retained Earnings was 100.32% in 2024 against a maximum downside of 1871832.37% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$3.3 million in 2021, then crashed by 119.8% to -$7.2 million in 2022, then plummeted by 51.61% to -$10.9 million in 2023, then skyrocketed by 100.02% to $2419.0 in 2024, then plummeted by 769461.68% to -$18.6 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Retained Earnings are -$18.6 million (Q3 2025), -$17.5 million (Q2 2025), and $10704.0 (Q1 2025).